



Universiteit
Leiden
The Netherlands

Langerhans cell histiocytosis : clues on pathogenesis and steps towards therapy

Bechan, I.G.

Citation

Bechan, I. G. (2013, March 6). *Langerhans cell histiocytosis : clues on pathogenesis and steps towards therapy*. Retrieved from <https://hdl.handle.net/1887/20594>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/20594>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/20594> holds various files of this Leiden University dissertation.

Author: Bechan, Indiradevi Gitanjali

Title: Langerhans cell histiocytosis : clues on pathogenesis and steps towards therapy

Issue Date: 2013-03-06

Stellingen

behorende bij het proefschrift

LANGERHANS CELL HISTIOCYTOSIS: CLUES ON PATHOGENESIS AND STEPS TOWARDS THERAPY

1. The transcriptional activity of beta-catenin might be aberrantly regulated in LCH cells and its absence might therefore be an important factor contributing to the pathogenesis of LCH. (This thesis)
2. The Malignant Histiocytosis Sarcoma Virus (MHSV) mouse model shows that viral transformation of a precursor for DC and macrophages can lead to transformation of CD8 α ⁺ CD207/Langerin⁺ DC and a phenotype resembling multisystem LCH as well as a phenotype of DC sarcoma. (This thesis)
3. The human anti-human CD1a monoclonal antibody CR2113 might be used as a therapeutic tool of a new dimension for LCH in the future. (This thesis)
4. Short telomeres specifically in the pathological LC in LCH suggests a survival mechanism of these cells similarly to that of malignant cells. (This thesis)
5. We propose a new model in which LCH does not arise from epidermal LCs but from misguided myeloid DC precursors. (Allen et al., J Immunol. 2010 Apr 15;184(8):4557-67)
6. Beta-catenin signaling in DCs is required to induce T-reg cells and suppress TH1/TH17 responses. (Manicassamy et al., Science. 2010 Aug 13;329(5993):849-53)

7. High prevalence, recurrent BRAF mutations in LCH indicate that it is a neoplastic disease that may respond to RAF pathway inhibitors. (Badalian-Very et al., Blood. 2010;116(11):1919-1923)
8. One of the remarkable and unique aspects of the recent history of rare disease research has been the evolving role of patient advocacy groups and the collaborative partnership that exists among such groups and the scientists who study rare diseases, as well as the government officials charged with overseeing medical research and regulatory processes. (Dunkle et al., Adv Exp Med Biol. 2010;686:515-25)
9. The future belongs to those who believe in the beauty of their dreams. (Eleanor Roosevelt, 1884-1962)
10. Doubt is not a pleasant condition, but certainty is absurd. (Voltaire, 1694-1778)
11. Nature is nowhere accustomed more openly to display her secret mysteries than in cases where she shows traces of her workings apart from the beaten path; nor is there any better way to advance the proper practice of medicine than to give our minds to the discovery of the usual law of nature by the careful investigation of cases of rarer forms of disease. (William Harvey, 1578-1657)

Leiden, 6 maart 2013

Anjali Bechan